Ovarian cancer neoadjuvant chemotherapy

Avril et al. [99] evaluated sequential [ F]-FDG-PET to predict patient outcome after the first and the third cycle of neoadjuvant chemotherapy in 33 patients with advanced-stage ovarian cancer. A significant correlation was observed between [ F]-FDG-PET metabolic response after the first (p = 0.008) and the third (p = 0.005) cycle of chemotherapy and overall survival. After the first cycle, a threshold of 20% SUV decrease for differentiation of metabolic responders and nonresponders revealed the following median overall survival 38.3 months for metabolic responders compared to 23.1 months for metabolic nonresponders. [Pg.168]

Therefore, [ F]-FDG-PET also appears to be a promising tool for early prediction of response to neoadjuvant chemotherapy in patients with ovarian cancer. [Pg.169]

N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W.A. Weber, M. Werner, H. Graeff, M. Schwaiger, W. Kuhn, Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer, J. Clin. Oncol. 23(30) (2005) 7445-7453. [Pg.188]

Bristow, R.E., Chi, D.S., (2006). Platinum -based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer a meta-analysis. Gynecol, oncol, 103(3), 1070-1076. [Pg.224]

Huober J, Meyer A, Wagner U, Wallwiener D (2002) The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. Cancer Res Clin Oncol 128 153-160... [Pg.262]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...